Servier UK

About Servier

Servier is an international pharmaceutical company governed by a non-profit foundation with its headquarters in Suresnes (France).

With a strong international presence in 148 countries and a turnover of 4 billion euros in 2016, Servier employs 21,000 people worldwide.

Corporate growth is driven by Servier's constant search for innovation in five areas of excellence: cardiovascular diseases, diabetes, cancers, immune-inflammatory diseases, and neurodegenerative diseases, as well as by its activities in high-quality generic drugs.

Being completely independent, the Group reinvests 25% of turnover (excluding generics) in research and development and uses all its profits for growth.

Servier was created in 1954, and in 1964 Servier UK was the first subsidiary to open, with just two employees.

 

Our R&D is specialised in 5 major axes 

Cardiovascular (Heart Failure)

Cancer (Solid tumours and haematological malignancies)

Immune-inflammatory (Auto-immune disease)

Diabetes (Type II diabetes)

Neuro-Psychiatric Diseases (Neurodegenerative disease)

 

Our current portfolio of medicinal products available in the UK is:

Coversyl Arginine (perindopril)

Coversyl Arginine Plus (perindopril and indapamide)

Diamicron MR (gliclazide)

Lonsurf (trifluridine/tipiracil)

Natrilix SR (indapamide)

Pixuvri (pixantrone)

Procoralan (ivabradine hydrochloride)

Protelos (strontium ranelate)  DISCONTINUED

Valdoxan (agomelatine)

 

UK14WEB0013(1)a DoP: December 2017